An interventional study of Fluoroscopy-guided endoscopic procedure in Radiation Exposure, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Fluoroscopy is an integral part of both basic and advanced gastrointestinal endoscopy procedures. Given the risks of radiation exposure and inherent limitations of preventive measures, there is a need for additional effective protective methods.
In this randomized trial, we will be comparing radiation exposure between a next generation fluoroscopy system and conventional fluoroscopy system during fluoroscopy-guided endoscopic procedures.
Fluoroscopy is an integral part of both basic and advanced gastrointestinal endoscopy procedures such as stricture dilation, enteral feeding tube placement, double balloon enteroscopy, endoscopic retrograde cholangiopancreatography (ERCP) and interventional endoscopic ultrasound (EUS). Use of fluoroscopy exposes patients, gastroenterologists and endoscopy support personnel to ionizing radiation. While exposure to high-dose-rate ionizing radiation has been shown to be associated with genomic instability, data indicate that exposure to even low-dose radiation, typically utilized for diagnostic imaging, may be associated with an increase in cancer mortality. The lifetime cancer risk is based on the effective dose (ED) of radiation received, which is measured in sieverts (Sv).
In a recent study conducted at a high-volume endoscopy center, the estimated dose equivalent at eye level was estimated to be 126 mSv for an endoscopist performing 500 therapeutic ERCPs per year. Consequently, exposure to ionizing radiation is considered a health hazard to patients as well as gastroenterologists and endoscopy support personnel. As such, appropriate measures to keep radiation exposure as low as reasonably achievable (ALARA) should be implemented. Professional societies such as the American Society for Gastrointestinal Endoscopy (ASGE) and the European Society of Gastrointestinal Endoscopy (ESGE) have published guidelines on radiation safety.
The two main sources of radiation during fluoroscopic procedures are the incident beam, which is the main source of radiation to the patient, and scatter radiation that emanates from the patient's body, which is the main source of radiation to individuals around the patient. Larger the radiation dose to the patient, the greater the scatter. Attempts to minimize radiation exposure include decreasing fluoroscopy time, using pulsed fluoroscopy, increasing the distance from radiation source, shielding, limiting magnification, using collimation, altering x-ray beam angulation, use of artificial intelligence fluoroscopy system, and avoiding use of C-arm units or over-couch x-ray systems. Use of personal protective equipment also reduces occupational exposure; however, many gastroenterologists performing ERCP do not routinely wear optimal protective clothing.
Given the risks of radiation exposure and inherent limitations of the preventive measures outlined, there is a need for additional effective protective methods that are easy to implement. The Soteria E-View system is an FDA-approved, next generation fluoroscopy system that is new to Orlando Health, for use in fluoroscopy-guided endoscopic procedures per standard of care (Omega Medical Imaging, Orlando Florida, USA). The system has been designed to minimize radiation exposure to patients and medical personnel by integrating second-generation artificial intelligence framework (for improved system performance and responsiveness), upgraded C-arm and tables (with enhanced lead flaps along the edges of the table), fluoroless positioning (to reduce reliance on fluoroscopy for positioning steps), reducing frame rate, and robotic system design (to enable automated positioning and movement).
The objective of the study is to compare the radiation exposure and scatter effect between the next generatoin fluoroscopy system and conventional fluoroscopy system during fluoroscopy-guided endoscopic procedures.
Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will undergo fluroscopy-guided endoscopic procedure using the next generation fluoroscopy system (Soteria, Omega Medical Imaging).
Procedure: Fluoroscopy-guided endoscopic procedure
Patients will undergo fluroscopy-guided endoscopic procedure using conventional fluoroscopy system (OEC Elite, GE Healthcare).
Procedure: Fluoroscopy-guided endoscopic procedure
Patients will be undergoing fluoroscopy-guided endoscopic procedure
Radiation scatter
Compare the level of radiation scatter during fluoroscopy-guided endoscopic procedures between the next generation fluoroscopy system and conventional fluoroscopy system.
Time frame: 1 day
Radiation exposure
Compare the level of radiation exposure in patients undergoing fluoroscopy-guided endoscopic procedures between the next generation fluoroscopy system and conventional fluoroscopy system.
Time frame: 1 day
Total procedure duration
Total duration of fluoroscopy-guided endoscopic procedure
Time frame: 1 day
Duration of fluoroscopy
Total duration of fluoroscopy usage during the endoscopic procedure
Time frame: 1 day
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orlando Health, Inc.